{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-25-000003","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.586718+00:00","generated_at":"2026-05-28T04:45:55.592825+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"iBio develops Activin E antibody for obesity; preclinical data shows sub-nanomolar binding","bullets":["Antibody targeting Activin E for cardiometabolic disorders and obesity, developed with AstralBio Inc.","Preclinical data: sub-nanomolar binding kinetics and complete blockade of Activin E signaling in human adipocytes.","Utilized iBio's AI platform to engineer antibodies targeting five epitopes on Activin E protein.","Corporate presentation updated to reflect the new antibody program; used in investor meetings."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-25-000003","json":"https://secwatch.observer/filing/0001420720-25-000003.json","markdown":"https://secwatch.observer/filing/0001420720-25-000003.md","text":"https://secwatch.observer/filing/0001420720-25-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072025000003/0001420720-25-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072025000003/ibio-20250110x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T04:45:55.592825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}